Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 16/20 | 0.93 |
| ▸ | CSF1R | P07333 | 1/20 | 0.93 |
| ▸ | LYN | P07948 | 1/20 | 0.93 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.93 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.93 |
| ▸ | FLT4 | P35916 | 1/20 | 0.93 |
| ▸ | KDR | P35968 | 1/20 | 0.93 |
| ▸ | BLK | P51451 | 1/20 | 0.93 |
| ▸ | BMX | P51813 | 1/20 | 0.93 |
| ▸ | JAK3 | P52333 | 1/20 | 0.93 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.93 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prn-1371 SCHEMBL16993012 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Prn-1371 SCHEMBL29360330 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993276 | 0.92 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993179 | 0.91 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Prn-1371 SCHEMBL30089820 | 0.91 | FGFR1 (0.90) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL18522475 | 0.91 | FGFR1 (0.86) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Prn-1371 SCHEMBL30089811 | 0.90 | FGFR1 (0.89) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993368 | 0.90 | FGFR1 (0.93) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL20434261 | 0.90 | FGFR1 (0.87) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16997097 | 0.89 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | claimed |
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2019-05-21 | — | — | US | claimed |
| EP-3102577-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-07-18 | — | — | EP | claimed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | claimed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | claimed |
| EP-3102577-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-12-14 | — | — | EP | claimed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | claimed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | claimed |
| EP-3102577-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3102577-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885FGFR2 3/4885CSF1R 104/4885 |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885FGFR2 3/4885CSF1R 104/4885 |
| US-10294223-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885FGFR2 3/4885CSF1R 104/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | FGFR1 1/4885FGFR2 3/4885CSF1R 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.